title: Cardiovascular disease in human immunodeficiency virus.
abstract: With widespread access to high-quality medical care as in Australia, human immunodeficiency virus (HIV) is now considered a chronic, treatable condition, with a good life expectancy. The use of combined highly active antiretroviral therapy has enabled effective suppression of the virus, but has also been associated with increased cardiac morbidity and mortality. Over representation of traditional cardiac risk factors, such as hyperlipidaemia and diabetes, as well as an increased incidence of ischaemic and non-ischaemic heart disease is now considered a major concern of treatment with antiretroviral therapy. Therefore, a contemporary management strategy for patients with HIV must include active prevention and treatment of cardiovascular risk. This review will outline the complex interplay between HIV infection, antiretroviral drug regimens and accelerated cardiovascular disease, with a particular focus on screening, prevention and treatment options in a contemporary Australian HIV population.
authors.affiliation: St Vincent's Hospital, Sydney, New South Wales, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Cheruvu
authors.forename: C J
authors.initials: CJ
authors.lastname: Holloway
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology; D014943:Global Health; D006678:HIV; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D015994:Incidence; D012307:Risk Factors
keywords: HIV; antiretroviral therapy; cardiovascular disease; cardiovascular screening